JESUS PAULA CARVALHO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina - Docente
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
16 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 16
- Everolimus plus anastrozole for female adnexal tumor of probable Wolffian origin (FATWO) with STK11 mutation(2021) ESTEVEZ-DIZ, Maria De Pilar; BONADIO, Renata Colombo; CARVALHO, Filomena Marino; CARVALHO, Jesus PaulaFemale adnexal tumor of probable Wolffian origin (FATWO) are a rare type of cancer that originates from Wolffian duct remnants. Due to its rarity, no standard systemic treatment is established for cases of recurrent or metastatic disease. Previous literature reported the use of platinum-based chemotherapy and c-Kit tyrosine kinase inhibitors for FATWO cases with c-Kit positive expression. Currently, however, the broader availability of next-generation sequencing (NGS) tests allows a better molecular characterization of rare cancer such as FATWO and a possibility for the use of personalized, targeted therapy. Previous case series that performed NGS for FATWO patients described the presence of STK11 mutations in a considerable number of cases, representing a potential target in this population. To our knowledge, we describe here the first case report of a patient with FATWO and STK11 mutation exhibiting a considerable and durable response after treatment with an mTOR inhibitor plus endocrine therapy.
- The fallopian tube origin of an ovarian carcinoma(2023) CARVALHO, Jesus Paula; SUAREZ, Giovanni Miglino
- Successful Pre-Treatment Ovarian Fresh Tissue Transplantation in a Cervical Cancer Patient Undergoing Radiation Therapy: A Case Report(2023) BERTOLAZZI, Marilia A.; GENTA, Maria Luiza Nogueira Dias; CARVALHO, Filomena; BARACAT, Edmund C.; CARVALHO, Jesus PaulaCervical cancer is one of the most frequent gynecological malignancies in Brazil, and most of the patients require pelvic radiotherapy as part of oncological treatment.Pelvic radiotherapy induces ovarian premature insufficiency in pre-menopausal women. This condition impacts the life quality and increases the risk of osteoporosis, obesity, cardiovascular, and neurodegenerative diseases in the middle and long term.Most of these patients have no access to hormonal replacement therapy. Techniques such as ovarian transposition have questionable results when aiming to preserve ovarian function. In this context, a promising alternative is the implantation of fresh ovarian tissue, outside the radiotherapy field, in the abdominal cavity (orthotopic implantation) or in other sites such as the forearm, breast, or subcutaneous tissue (heterotopic implantation).Here we report a successful case of autologous implantation of fresh ovarian tissue in the inner thigh of a young patient with advanced cervical cancer, who was a candidate for concurrent chemoradiotherapy.
- Fertility preservation in gynecologic cancer patients(2023) PESSINI, Suzana Arenhart; CARVALHO, Jesus Paula; REIS, Ricardo dos; SILVA FILHO, Agnaldo Lopes da; PRIMO, Walquiria Quida Salles Pereira
- Management of cervical cancer patients during the COVID-19 pandemic: a challenge for developing countries(2020) ESTEVEZ-DIZ, Maria del Pilar; BONADIO, Renata Colombo; MIRANDA, Vanessa Costa; CARVALHO, Jesus PaulaDuring the COVID-19 pandemic, health services worldwide are going through important adaptations to assist patients infected with COVID-19, at the same time as continuing to provide assistance to other potentially life-threatening diseases. Although patients with cancer may be at increased risk for severe events related to COVID-19 infection, their oncologic treatments frequently cannot be delayed for long periods without jeopardising oncologic outcomes. Considering this, a careful consideration for treatment management of different malignancies is required. Cervical cancer is concentrated mainly in low-middle income countries (LMICs), which face particular challenges during the COVID-19 pandemic due to the scarcity of health resources in many places. Although cervical cancer is the fourth cause of cancer death among women, it receives little attention from international Oncology societies and scientific research studies. In this review paper, we discuss the cervical cancer landscape and provide specialists recommendations for its management during the COVID-19 pandemic, particularly focused on LMICs' reality.
- Autologous heterotopic fresh ovarian graft: technique description(2023) BERTOLAZZI, Marilia Albanezi; FERNANDES, Rodrigo Pinto; GENTA, Maria Luiza Nogueira Dias; BARACAT, Edmund Chada; CARVALHO, Jesus Paula
- Dysregulation of Transcription Factor Networks Unveils Different Pathways in Human Papillomavirus 16-Positive Squamous Cell Carcinoma and Adenocarcinoma of the Uterine Cervix(2021) BISPO, Saloe; FARIAS, Ticiana D. J.; ARAUJO-SOUZA, Patricia Savio de; CINTRA, Ricardo; SANTOS, Hellen Geremias dos; JORGE, Natasha Andressa Nogueira; CASTRO, Mauro Antonio Alves; WAJNBERG, Gabriel; SCHERER, Nicole de Miranda; GENTA, Maria Luiza Nogueira Dias; CARVALHO, Jesus Paula; VILLA, Luisa Lina; SICHERO, Laura; PASSETTI, FabioSquamous cell carcinoma (SCC) and adenocarcinoma (ADC) are the most common histological types of cervical cancer (CC). The worse prognosis of ADC cases highlights the need for better molecular characterization regarding differences between these CC types. RNA-Seq analysis of seven SCC and three ADC human papillomavirus 16-positive samples and the comparison with public data from non-tumoral human papillomavirus-negative cervical tissue samples revealed pathways exclusive to each histological type, such as the epithelial maintenance in SCC and the maturity-onset diabetes of the young (MODY) pathway in ADC. The transcriptional regulatory network analysis of cervical SCC samples unveiled a set of six transcription factor (TF) genes with the potential to positively regulate long non-coding RNA genes DSG1-AS1, CALML3-AS1, IGFL2-AS1, and TINCR. Additional analysis revealed a set of MODY TFs regulated in the sequence predicted to be repressed by miR-96-5p or miR-28-3p in ADC. These microRNAs were previously described to target LINC02381, which was predicted to be positively regulated by two MODY TFs upregulated in cervical ADC. Therefore, we hypothesize LINC02381 might act by decreasing the levels of miR-96-5p and miR-28-3p, promoting the MODY activation in cervical ADC. The novel TF networks here described should be explored for the development of more efficient diagnostic tools.
- Modified Laparoscopic Uterosacral Ligament Suspension in Patients with Gynecologic Tumors and Advanced Uterovaginal Prolapse(2016) FAVERO, Giovanni; BAESSLER, Kaven; HADDAD, Jorge; PFIFFER, Tatiana; BARACAT, Edmund Chada; CARVALHO, Jesus Paula; BORTOLINI, Maria AugustaObjectives: To evaluate the feasibility and safety of a novel approach for concomitant endoscopic treatment of gynecologic tumors and advanced uterovaginal prolapse. Methods: Prospective pilot study with women affected by gynecologic tumors synchronically with uterovaginal prolapse. Patients underwent laparoscopy for the oncologic treatment in parallel with uterosacral ligament suspension (USLS) and culdoplasty. Patients were assessed in regard to (1) feasibility and safety and (2) objective and subjective efficacy of the combined procedure. Results: Six women were endoscopically operated without conversion. The USLS/culdoplasty procedure accounted for 16% of the total operative time. Average operative time, blood loss and length of hospitalization were favorable. No major complications were observed during and after the surgeries. The mean follow-up was 20.3 months. Postoperative POP-Q measurements showed important improvements in the anterior and apical vaginal compartments and all patients were cancer free at the latest follow-up visit. Conclusion: Gynecologic tumors associated with advanced uterovaginal prolapse may be successfully treated by one-stage laparoscopic operation.
- Immune checkpoint inhibitors: here to stay(2023) CARVALHO, Filomena Marino; DIZ, Maria Del Pilar Estevez; CARVALHO, Jesus Paula
- Complete Clinical Response in Stage IVB Endometrioid Endometrial Carcinoma after First-Line Pembrolizumab Therapy: Report of a Case with Isolated Loss of PMS2 Protein(2020) CARVALHO, Jesus Paula; GIGLIO, Auro Del; ACHATZ, Maria Isabel; CARVALHO, Filomena MarinoEndometrial cancer is the only gynecological cancer that is rising in incidence and associated mortality worldwide. Although most cases are diagnosed as early stage disease, with chances of cure after primary surgical treatment, those with advanced or metastatic disease have a poor prognosis because of the quality of treatment options that are currently available. Mismatch repair (MMR)-deficient cancers are susceptible to programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 inhibitors. The US Food and Drug Administration granted accelerated approval to pembrolizumab for MMR-deficient tumors, the first tumor-agnostic approval for a drug. We present a case of stage IV endometrioid endometrial carcinoma with isolated PMS2 protein loss, in which treatment with first-line pembrolizumab therapy achieved a complete clinical and pathological response of tumor. (c) 2020 The Author(s).